The role of neuronal regulation of human cardiovascular function remains incompletely 25 elucidated, especially during exercise. Here we, by positron emission tomography, 26 monitored tissue-specific blood flow (BF) changes in nine healthy young men during 27 femoral arterial infusions of norepinephrine (NE) and phentolamine. At rest, the α-28 adrenoceptor agonist NE reduced BF by ~40%, similarly in muscles (from 3.2±1.9 to 29 1.4±0.3 ml · min -1 · 100 g -1 in m. quadriceps femoris), bone (from 1.1±0.4 to 0.5±0.2 ml 30 · min -1 · 100 g -1
femoral arterial infusions of norepinephrine (NE) and phentolamine. At rest, the α-28 adrenoceptor agonist NE reduced BF by ~40%, similarly in muscles (from 3.2±1.9 to 29 1.4±0.3 ml · min -1 · 100 g -1 in m. quadriceps femoris), bone (from 1.1±0.4 to 0.5±0.2 ml 30 · min -1 · 100 g -1
) and adipose tissue (AT) (from 1.2±0.7 to 0.7±0.3 ml · min -1 · 100 g -1 ). 31
During exercise, NE reduced exercising muscle BF by ~16%. BF in AT was reduced 32 similarly as at rest. The α-adrenoceptor antagonist phentolamine increased BF similarly 33 in the different muscles and other tissues of the limb at rest. During exercise, BF in 34 inactive muscle was increased 3.4-fold by phentolamine compared to exercise without 35 drug, but BF in exercising muscles was not influenced. Bone and AT (p=0.055) BF 36
were also increased by phentolamine in the exercise condition. NE increased and 37 phentolamine decreased oxygen extraction in the limb during exercise. We conclude 38 that inhibition of α-adrenergic tone markedly disturbs the distribution of BF and oxygen 39 extraction in the exercising human limb by increasing BF especially around inactive 40 muscle fibers. Moreover, although marked functional sympatholysis also occurs during 41 exercise, the arterial NE infusion that mimics the exaggerated sympathetic nerve 42 activity commonly seen in patients with cardiovascular disease was still capable of 43 directly limiting BF in the exercising leg muscles. 44 3
Introduction 49
Skeletal muscle blood flow is dramatically increased in response to exercise, but so is 50 also muscle sympathetic nerve activity, which should constrict the blood vessels of the 51 exercising limb. This paradoxical phenomenon has been investigated since the 1930s 52 when Rein reported that activation of sympathetic nerves decreased blood flow to a 53 greater extent in a resting than in an exercising dog hindlimb (36). Later, Remensnyder 54
and colleagues observed reduced vasoconstrictor responses in an exercising limb or 55 muscle in response to activation of sympathetic nerves or local intra-arterial infusion of 56 norepinephrine (NE), and coined the term "functional sympatholysis" to describe the 57 phenomenon (37). However, as extensively reviewed by Thomas and Segal (47) as well 58
as Delp and O'Leary (9), functional sympatholysis has not been a consistent finding: 59 different studies have reported variable results ranging from well-preserved α-60 adrenergic vasoconstriction to complete inhibition of vasoconstriction during exercise. 61
Differences in methods, animal species, and interpretations of the study results are 62 likely to account for at least some of the discrepancies (9; 47). 63
64
In addition to the functional sympatholysis that is still incompletely understood in 65 humans, it has been proposed that there is always some α-adrenergic vasoconstrictor 66 tone even in the exercising muscle (3; 4; 9; 47), which restrains blood flow to the 67 actively exercising muscles and prevents the fall in systemic blood pressure that would 68 otherwise occur (30). This idea stems largely from studies showing that blood flow to 69 an exercising limb is increased upon interruption of sympathetic outflow or 70 pharmacological antagonism of α-adrenoceptors (3; 47) and extrapolative calculations 71 (3; 4; 9). However, the interpretation remains unverified especially in humans, since no 72 technique has been able to separately monitor contracting and inactive muscle fibers 73
Results

197
Norepinephrine infusions -rest 198
At rest, NE reduced blood flow similarly (by 44-56 %) in all muscles (drug*muscle 199 interaction p = 0.67) and also in bone and adipose tissue, while also MAP was 200 increased slightly, but consistently (Table 1) (Table 1) . 207
208
Norepinephrine infusions -exercise 209
During exercise, the higher dose rate of NE reduced active muscle blood flow by ~16 210 % (QF) (drug*muscle interaction p = 0.99 in QF musculature), but it did not affect 211 inactive muscle blood flow, which remained on resting levels also during exercise 212 (Table 2) . Bone blood flow, which was increased in response to exercise (p < 0.001), 213
was not affected by NE during exercise, but blood flow in adipose tissue was reduced 214 to a similar extent as at rest, by 39 %. Blood flow was consistently higher in VI 215 compared to all other three parts of the working QF. Systemic blood pressure remained 216 unchanged during exercise during these local intra-arterial NE infusions, indicating that 217 systemic hemodynamics were not affected and that the blood flow changes were not 218 driven by changes in perfusion pressure (Table 2) . Representative blood flow responses 219 are shown in Figure 3 . Venous oxygen content was lower and the oxygen extraction 220 fraction was higher during the higher dose rate of NE compared to control exercise 221 (Table 2) . 222
223
Vascular conductance during norepinephrine 224
Because of the increased mean arterial and thus perfusion pressure in response to 225 exercise (p < 0.05), the extent of exercise-induced sympatholysis was judged from 226 vascular conductance estimates, which are reported in Table 3 . Overall, the changes in 227 conductance in response to NE infusions at rest and during exercise followed the 228 patterns of blood flow changes in the different tissues investigated. The percent change 229 of vascular conductance in response to the NE infusions indicated that the NE-induced 230 reduction of conductance by ~40 % in m. quadriceps femoris at rest was greatly 231 attenuated during exercise, as the reductions were only about 15 % and 11 % from 232 control exercise during the low-and high-rate NE infusions (Figure 4) . The NE-evoked 233 reductions of vascular conductance tended to be attenuated also in the inactive 234 hamstring muscles in response to exercise, but without statistical significance (p=0.09) 235 because of the large inter-individual variability, but the NE effect was clearly 236 attenuated in bone (Figure 4) . On the other hand, exercise induced no attenuation of the 237 NE-evoked reduction of conductance in subcutaneous adipose tissue (Figure 4) . 238
239
Phentolamine infusions -rest and exercise 240
Two subjects with the largest thigh volumes (~12 L) and thus the highest infused doses 241 of phentolamine did not maintain their blood pressure during the drug infusion. Their 242 blood pressure fell below acceptable levels (<100/60 mmHg), associated with severe 243 fainting symptoms, and the drug infusions had to be interrupted. One subject 244 experienced these symptoms immediately after the start of the infusion at rest, and the 245 other one after the completion of the resting infusion. All other subjects were able to 246 11 maintain their normal blood pressure, by the compensatory mechanism of increased 247 heart rate (Table 4) , and the phentolamine results are therefore reported here from 8 248 subjects at rest and 7 subjects during exercise. Phentolamine similarly elevated blood 249 flow in different muscles (drug*muscle interaction p = 0.59) and other tissues of the 250 limb at rest (Table 4) . Representative blood flow responses are shown in Figure 5 . The 251 femoral venous oxygen content was higher and the OEF lower during the phentolamine 252 infusion compared to resting baseline conditions (Table 4) . 253
254
During exercise, the ratio of active-to-inactive muscle blood flow was reduced from 255
18.3 ± 10.7 in the control condition with no drug to 5.3 ± 4.0 during phentolamine, 256 since blood flow in inactive muscle increased 3.4-fold, but blood flow in exercising 257 muscle remained similar to that in the control exercise condition (Table 4 ). Blood flow 258 was higher in VI compared to VL and RF. Representative blood flow responses are 259 shown in Figure 5 . Similarly as at rest, the femoral venous oxygen content was higher 260 and the OEF lower during the phentolamine infusion compared to control exercise 261 (Table 4) . Non-significant changes in systemic blood pressure indicated that the blood 262 flow changes were not driven by changes in perfusion pressure (Table 4) interpretations have remained equivocal (9; 47). The present study was set out to clarify 321 these inconsistencies. We first characterized tissue-and muscle-specific blood flow 322 responses to local intra-arterial infusions of NE at rest and during one-leg knee-323 extension exercise by applying the same principles as in some previous studies (6; 15). conductance also tended to be smaller in the inactive hamstring muscles is likely 337 explained by the fact that the NE infusion was started, deliberately, after 2 min of 338 steady-state exercise and thus drug delivery was mostly directed to exercising muscle. 339
It may also be related to factors other than α-adrenergic regulation, since we have 340 previously found that for some reason the reduction of inactive muscle blood flow 341 induced by nitric oxide synthase inhibition also disappears during exercise (22). 342
Moreover, NE induced similar vasoconstriction in adipose tissue at rest and during 343 exercise. This reduces total limb blood flow, and may have caused some 344 15 underestimation of the true exercise-induced sympatholysis, confined to contracting 345 muscles, in previous studies employing whole limb blood flow determinations to 346 estimate muscle blood flow (9; 47). Although prolonged intravenous infusion of NE is 347 also known to enhance adipose tissue blood flow, our observation of reduced adipose 348 tissue blood flow in response to an acute local NE infusion is in line with the notion 349 that NE invariably causes α-adrenergic vasoconstriction in adipose tissue (39) . 350
351
From animal experiments, it is known that exercise modulates α-adrenergic tone 352 differently along the arterial tree (1). This aspect, unfortunately, cannot be addressed in 353 humans in vivo. On the other hand, it is also known that exercise modulates α-354 adrenergic tone differently in oxidative and glycolytic muscles in animals (45), but so 355 far this has never been investigated in humans. Some support for possible differences in 356 α-adrenergic regulation between different human muscles stems from previous findings 357 that blood flow is consistently higher and resistance lower in the muscles known to be 358 more oxidative (21). Robust differences between QF muscle components were also 359 evident in the present study at rest and during exercise, especially between VI and RF, 360 which are known to consist mostly of type I and type II muscle fibers, respectively (12; 361 25; 35). However, since NE reduced and phentolamine increased blood flow similarly 362 in all of these different muscles, our findings suggest that no marked differences exist 363 in α-adrenergic vascular control in different muscles in humans. One likely explanation 364 for this species-specific difference is that in contrast to animals, muscles in humans are 365 not solely oxidative or glycolytic (25; 35). Nevertheless, as the α-adrenoceptor subtype 366 distributions may vary according to skeletal muscles with differing functions (2; 32), 367 inclusion of receptor subtype-specific agonists and antagonists (10; 40; 50; 51) would 368 certainly provide valuable further insights. 369
Methodological considerations 370
The present study has some limitations. Since inhibition of β-adrenoceptors was not 371 applied in the present study, in some subjects some β-adrenergic vasodilation may have 372 occurred during high-dose NE, especially during exercise when 10-fold higher dose 373 rates than at rest were employed to overcome a possible dilution effect caused by 374 greater total limb blood flow. This may have resulted in overestimation of true 375 exercise-induced sympatholysis. However, we and others (47) do not believe that the 376 overestimation is substantial, since inhibition of β-adrenoceptors had no effect on 377 functional sympatholysis in mice (48) and the β-agonist isoproterenol did not attenuate 378 sympathetic vasoconstriction in rats (46). Moreover, the exercise model was one of 379 fairly low-intensity, small muscle mass exercise, and the results might be different 380 during high-intensity whole-body exercise, when epinephrine release from the adrenal 381 glands is stimulated (3; 4; 9). Compared to epinephrine, NE has very low potency to 382 activate vasodilating β 2 -adrenoceptors (44), which is also likely the reason why β-383 adrenoceptor inhibition does not affect arterial responses induced by NE (32). 384
Nevertheless, low-to-moderate-intensity small muscle mass exercise is in practice the 385 model that has been and can be used in addressing these phenomena in humans (10; 40; 386 50; 51). Moreover, the results obtained here only apply to young healthy males, and it 387 is unknown whether factors dependent on gender, age or diseases have potential to 388 modify these findings (13; 52). Finally, saline infusion during the control trials matched 389 for infusion rates of the experimental conditions, to rule out bias effect of infusion 390 versus actual pharmacological effects, was not applied, as we should have then 391 performed also our control trials two times (due to two different NE infusion rates, also 392 during exercise). This would have increased the total radiation dose to an unacceptable 393 level. However, we also think that all of these effects we document in our report are 394 highly unlikely to occur just as a result of infusions alone, but are reasonably caused by 395 true pharmacological effects. 396
397
Perspectives 398
Even though the present study was performed in healthy young men and was 399 experimental in nature, there are several novel insights provided by the results with 400 potential relevance for clinical populations. Exaggerated sympathetic nerve activity 401 during exercise is commonly seen in patients with heart failure and hypertension (27; 402 33), and the results of the present study clearly suggest that an overactive sympathetic 403 nervous system has the potential to limit exercising blood flow and contribute to the 404 exercise intolerance that is frequently observed in these patients. It may also be that in 405 these patients, who often have low aerobic fitness, sympathetic nerve activation is 406 triggered earlier (in terms of exercise intensity) compared to healthy subjects, because 407 of metabolically evoked reflex activation (27; 33). This may also cause problems in 408 cardiac function (7). Still, according to the present results, inhibition of α-adrenergic 409 tone does not lead to enhanced blood flow in exercising muscles; the modulation 410 occurred solely in the inactive muscles and other tissues of the limb. The extrapolation 411 of this to clinical outcomes is not straightforward, however, since local administration 412 of phentolamine did not alter maximal limb blood flow in heart failure patients (28). 413
Moreover, in contrast to healthy subjects, functional sympatholysis is known to be 414 impaired in physically inactive patients (42), and particularly in subjects with 415 hypertension (49), which likely also contributes to their responses such as exaggerated 416 rises in blood pressure and blunted reductions in systemic vascular resistance during 417 exercise. However, as physical activity is also well known to enhance fitness and 418 induce fairly long-lasting post-exercise hypotension, it is likely that especially exercise 419 training can ameliorate impairments in functional sympatholysis and normalize these 420 exaggerated blood pressure responses. Nevertheless, some vasoconstriction might also 421 be needed in active muscles during very high-intensity whole-body exercise especially 422 in healthy humans (3; 4; 9), but all of these aspects warrant further methodologically 423 robust experiments in humans and in conscious animals in health and disease. 3.2 ± 1.9 1.8 ± 0.7* 1.4 ± 0. 36.1 ± 6.7 31.8 ± 5.1 28.9 ± 3.4** -VL (ml · min -1 · 100 g -1 ) 31.1 ± 8.1 28.5 ± 8.8 26.8 ± 7.2** -RF (ml · min -1 · 100 g -1 )
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